Geneva Capital Management LLC purchased a new stake in Baxter International Inc. (NYSE:BAX – Free Report) in the 3rd quarter, Holdings Channel.com reports. The institutional investor purchased 57,552 shares of the medical instruments supplier’s stock, valued at approximately $1,381,000.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. BlackRock Inc. bought a new position in Baxter International during the 2nd quarter worth $1,744,874,000. Pzena Investment Management LLC acquired a new stake in shares of Baxter International during the second quarter worth $1,392,098,000. Equity Investment Corp acquired a new stake in shares of Baxter International during the second quarter worth $146,815,000. Bank of America Corp DE bought a new stake in shares of Baxter International in the second quarter valued at about $132,993,000. Finally, Aberdeen Group plc boosted its position in shares of Baxter International by 16,776.9% in the third quarter. Aberdeen Group plc now owns 3,743,975 shares of the medical instruments supplier’s stock valued at $89,855,000 after acquiring an additional 3,721,791 shares during the period. 90.19% of the stock is owned by institutional investors and hedge funds.
Baxter International Stock Down 1.1%
Shares of NYSE BAX opened at $25.53 on Tuesday. The company has a current ratio of 1.79, a quick ratio of 1.19 and a debt-to-equity ratio of 1.20. The company has a market cap of $13.21 billion, a price-to-earnings ratio of -18.10, a PEG ratio of 3.78 and a beta of 0.68. Baxter International Inc. has a 12 month low of $15.73 and a 12 month high of $30.00. The stock has a 50-day moving average price of $24.53 and a two-hundred day moving average price of $21.70.
Baxter International (NYSE:BAX – Get Free Report) last posted its earnings results on Thursday, October 29th. The medical instruments supplier reported $0.58 EPS for the quarter, topping analysts’ consensus estimates of $0.52 by $0.06. Baxter International had a negative net margin of 6.23% and a positive return on equity of 16.23%. The firm had revenue of $2.98 billion during the quarter, compared to analysts’ expectations of $2.91 billion. During the same quarter in the prior year, the business earned $0.69 earnings per share. The business’s revenue for the quarter was up 5.0% compared to the same quarter last year. As a group, analysts forecast that Baxter International Inc. will post 2.10 earnings per share for the current fiscal year.
Baxter International Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Monday, January 4th. Investors of record on Friday, November 27th will be given a dividend of $0.01 per share. This represents a $0.04 dividend on an annualized basis and a yield of 0.2%. The ex-dividend date is Friday, November 27th. Baxter International’s dividend payout ratio is currently -2.84%.
Wall Street Analysts Forecast Growth
Several research firms recently commented on BAX. Citigroup decreased their price target on shares of Baxter International from $28.00 to $27.00 and set a “neutral” rating on the stock in a research note on Monday, October 5th. UBS Group lifted their price objective on shares of Baxter International from $19.00 to $25.00 and gave the stock a “hold” rating in a research note on Tuesday, July 28th. JPMorgan Chase & Co. dropped their price objective on shares of Baxter International from $26.00 to $25.00 and set a “neutral” rating for the company in a research note on Friday, October 30th. Wolfe Research initiated coverage on shares of Baxter International in a report on Tuesday, October 20th. They issued a “peer perform” rating for the company. Finally, Weiss Ratings upgraded shares of Baxter International from a “sell (d-)” rating to a “sell (d)” rating in a research report on Friday, October 30th. One analyst has rated the stock with a Buy rating, ten have given a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat.com, Baxter International has an average rating of “Reduce” and a consensus target price of $23.27.
Get Our Latest Stock Report on Baxter International
About Baxter International
Baxter International is a global healthcare company that develops and supplies products used in hospitals, clinics and other care settings. Its offerings include intravenous solutions and administration sets, infusion pumps, medication-delivery systems, and products for surgical and hospital care. The company also provides patient-monitoring and connected-care technologies, including products associated with Hillrom, which Baxter acquired in 2021. Its products and services support healthcare professionals and patients in countries around the world.
Featured Articles
- Five stocks we like better than Baxter International
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Want to see what other hedge funds are holding BAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Baxter International Inc. (NYSE:BAX – Free Report).
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.
